induced pluripotent stem cells

[Nature Reviews Neurology] The authors discuss ongoing efforts to leverage genomic data from patients using cellular reprogramming technologies to recapitulate complex brain systems and build in vitro discovery platforms.

[Communications Medicine] The authors reported a series of ten COVID-19 patients with audiovestibular symptoms such as hearing loss, vestibular dysfunction and tinnitus.

[Frontiers in Endocrinology] The authors differentiated iPSC from one donor into dendritic cells, macrophages, endothelial cells, and β-cells, and engineered T cell avatars from the same donor to provide an in vitro platform to study genetic influences on critical cellular interactions.

[Science Advances] Researchers aimed to identify the causal pathogenic mutation in an early-onset osteoarthritis family, followed by functional studies in human iPSCs in an in vitro organoid cartilage model.

[EdiGene, Inc.] EdiGene, Inc. has entered into a research collaboration with the University of Wisconsin–Madison as part of the company’s effort of translating proprietary LEAPER™ RNA editing technology into in vivo therapies.

[Shoreline Biosciences] Dendreon Pharmaceuticals and Shoreline Biosciences, a biotechnology company developing allogeneic off-the-shelf, standardized, and targeted natural killer and macrophage cellular immunotherapies derived from iPSC for cancer, announced an alliance to advance the future of iPSC-derived cellular therapies.